I agree they will likely partner this yr, I would prefer that it were for P as its a stand alone at this point for CTIX and I'd love for them to develop B and K at least to the point of beginning a registration trials as they are true platform drugs if things continue on the current path. Because B&K are platform drugs I'd prefer that CTIX partner THEM up on an indication by indication basis unless the offer is OF COURSE, too goo to refuse. I suspect Leo may want to see what he can discern from the P trial before he partners B&K prior to completing their current trials.